Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials
Edward J. Gane*, Stephen Pianko, Stuart K. Roberts, Alexander J. Thompson, Stefan Zeuzem, Eli Zuckerman, Ziv Ben-Ari, Graham R. Foster, Kosh Agarwal, Alex L. Laursen, Jan Gerstoft, Wei Gao, Hsueh Cheng Huang, Brian Fitzgerald, Doreen Fernsler, Jerry J. Li, Anjana Grandhi, Hong Liu, Feng Hsiu Su, Shuyan WanZhen Zeng, Huei Ling Chen, Frank J. Dutko, Bach Yen T. Nguyen, Janice Wahl, Michael N. Robertson, Eliav Barr, Wendy W. Yeh, Rebeca M. Plank, Joan R. Butterton, Rafael Esteban
Dive into the research topics of 'Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials'. Together they form a unique fingerprint.